$0.22
0.00 (-1.70%)
Open$0.23
Previous Close$0.22
Day High$0.23
Day Low$0.22
52W High$3.87
52W Low$0.22
Volume—
Avg Volume1.36M
Market Cap3.74M
P/E Ratio—
EPS$-4.45
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+12,901.8% upside
Current
$0.22
$0.22
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 832.6K | 1.18M | 3.56M |
| Net Income | -88,006,029 | -111,966,958 | 452.9K |
| Profit Margin | -10,567.2% | -10,038.8% | 12.7% |
| EBITDA | -88,845,248 | -119,314,370 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -29.3% | -29.3% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |